These trials completed more than 12 months ago and should have reported results.
These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.
These trials have problematic data on the registry. Details why »
|Status||Trial ID||Title||Completion date||Category|
|Completed, but no date, and reported results Terminated||2006-002324-41||A Cancer Research UK Randomised Multicentre Phase II Trial of the DNA-hypomethylating Agent, 5-Aza-2'-deoxycytidine(Decitabine) given intravenously in Combination with Carboplatin, versus Carboplatin ...||bad-data|
|Reported results Terminated||2006-002348-27||A Cancer Research UK Phase II Proof of Principle Trial of the activity of the PARP-1 inhibitor, AG-014699, in known carriers of a BRCA 1 or BRCA 2 mutation with locally advanced or metastatic breast o...||2015-01-22||due-trials|
|Reported results Terminated||2006-004149-40||A Cancer Research UK randomised phase II trial of ATN-224 (copper binding agent) in combination with letrozole versus letrozole alone in post-menopausal women with recurrent, oestrogen and/or progeste...||2007-10-04||due-trials|
|Exempt, with results||2007-003240-30||A Cancer Research UK Phase I/II Open Label Study to Evaluate the Safety, Endocrine Effects, and Anti-tumour Activity of Abiraterone Acetate (CB7630) in Patients with Oestrogen (ER) or Androgen Recepto...||not-yet-due|
|Ongoing, reported early||2007-005752-16||A Cancer Research UK randomised phase II trial of ATN-224 (copper binding agent) in combination with exemestane versus exemestane alone in post-menopausal women with recurrent or advanced, oestrogen a...||not-yet-due|
|Reported results Terminated||2008-004828-23||A Cancer Research UK Phase II Trial to compare [11C]choline and [18F]choline each given as a single administration via intravenous injection for imaging patients with metastatic prostate cancer||2011-06-06||due-trials|
|Exempt, with results||2008-004829-42||A Cancer Research UK Phase I/IIa Trial of an Oral Notch Inhibitor (MK-0752) in Combination with Gemcitabine in Patients with Stage IV Pancreatic Cancer||not-yet-due|
|Exempt, with results||2008-005542-23||A CCLG/Cancer Research UK Phase I Trial of AT9283 (a selective inhibitor of Aurora kinases) given for 72 hours every 21 days via intravenous infusion in children and adolescents with relapsed and refr...||not-yet-due|
|Exempt, with results Terminated||2009-016952-36||A Cancer Research UK Phase I trial of AT9283 (a selective inhibitor of aurora kinases) given over 72 hrs every 21 days via intravenous infusion in children and adolescents aged 6 months to 18 years wi...||2014-07-01||not-yet-due|
|Exempt||2012-002029-31||A Cancer Research UK Phase I/II study to compare [124I]mIBG PET/CT to [123I]mIBG imaging in patients with metastatic neuroblastoma||not-yet-due|
|Exempt||2014-000070-19||A Cancer Research UK Phase I Study of MOv18 IgE, a first in class chimeric IgE antibody against folate receptor-α, in patients with advanced solid tumours||not-yet-due|
|Ongoing||2014-004388-20||A Cancer Research UK randomised, double-blind, placebo-controlled Phase IIa trial of AMG 319 given orally as a neoadjuvant therapy in patients with human papillomavirus (HPV) positive and negative hea...||not-yet-due|